News Quantified

CDXC – chromadex corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]

ChromaDex Co. (NASDAQ: CDXC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.

ChromaDex Corporation Reports First Quarter 2024 Financial Results [Yahoo! Finance]

ChromaDex Corporation Reports First Quarter 2024 Financial Results

An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% Undervalued [Yahoo! Finance]

-10.2%

BEAT

-8.6%

BEAT

-11.3%

BEAT

-2.4%

BEAT

Form 8-K ChromaDex Corp. For: May 08

Form 10-Q ChromaDex Corp. For: Mar 31

Form ARS ChromaDex Corp. For: Dec 31

Form DEFA14A ChromaDex Corp.

Form DEF 14A ChromaDex Corp. For: Apr 25

Top News Gainers

3/24 Form CT ORDER ChromaDex Corp. 12.8%

4/20 ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) 11.2%

8/14 ChromaDex Announces $7 Million Private Placement of Common Stock 10.3%

11/20 European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food 8.0%

2/27 Form 4 ChromaDex Corp. For: Feb 25 Filed by: Jaksch Frank L Jr 7.8%

11/12 Form 8-K ChromaDex Corp. For: Nov 12 7.4%

3/10 Q4/2019 12/31/2019 EPS -0.110 ZacksConsensus -0.120 ActVsEst 0.010 - Beat 7.3%

10/15 Chromadex Corp (NASDAQ: CDXC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 7.3%

1/6 First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension 6.8%

4/2 Form CT ORDER ChromaDex Corp. 6.5%

Top News Decliners

11/4 ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 -15.5%

2/25 ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020 -15.0%

3/17 Chromadex Corp (NASDAQ: CDXC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -14.5%

5/28 Chromadex Corp (NASDAQ: CDXC) was given a new $7.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -9.3%

3/31 Form 3 ChromaDex Corp. For: Mar 27 Filed by: Jordan Megan Kern -8.0%

12/16 ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen® -7.4%

3/23 Cellular Health Market Leader Tru Niagen® Launches Online in Australia -7.3%

1/10 Form 8-K ChromaDex Corp. For: Jan 07 -6.6%

10/1 Chromadex Corp (NASDAQ: CDXC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -5.8%

11/12 ChromaDex Corporation (CDXC) Q3 2019 Earnings Call Transcript [The Motley Fool] -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day